New eczema cream shows promise in early trial
NCT ID NCT06891040
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested a cream called VC005 on 118 adults with mild to moderate atopic dermatitis (eczema). The study compared the cream to a placebo to see if it safely reduces eczema symptoms like itching and skin redness. Results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VC005 cream
- What this could lead to
- If successful, this could point toward a new topical treatment to ease eczema symptoms like itching and redness.
- What could go wrong
- This is an early Phase 2 study with only 118 people, so results may not confirm effectiveness or safety for wider use. The cream may not work better than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences Hospital of Skin Disease
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?